drugset / Trial / NCT02291913
Everolimus Combined With Anti-estrogen Therapy in Hormone-Receptor-Positive HER-2 Negative Advanced Breast Cancer
NaSingle-groupOpen-labelTreatment
Summary
Many patients with ER-positive or PR-positive breast cancer are treated with endocrine therapy. Although most ER/PR-positive tumors initially respond to hormonal therapy, patients often experience disease progression. Everolimus, in combination with exemestane, has shown activity in endocrine-resistant disease. This study will evaluate the efficacy of Everolimus+ anti-estrogen therapy in patients with ER-positive metastatic breast cancer who have progressed after receiving anti-estrogen therapy.
Timeline
- Start
- 2014-12-18
- Primary completion
- 2019-01-31
- Completion
- 2019-01-31
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Everolimus | Small molecule | 10 mg | Oral |
| Background | Anastrozole | Other / unclassified | — | — |
| Background | Exemestane | Small molecule | — | — |
| Background | Fulvestrant | Small molecule | — | — |
| Background | Letrozole | Other / unclassified | — | — |
| Background | Tamoxifen | Small molecule | — | — |
| Background | Toremifine | Unknown | — | — |